Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 17/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.46 |
| ▸ | CCKAR | P32238 | 3/20 | 0.45 |
| ▸ | CCKBR | P32239 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30717859 | 0.99 | OPRD1 (0.50) | OPRD1OPRM1OPRK1IL23RCCKAR | |
| SCHEMBL30717895 | 0.98 | OPRD1 (0.49) | OPRD1OPRM1OPRK1IL23RCCKAR | |
| SCHEMBL30717849 | 0.96 | OPRD1 (0.52) | OPRD1OPRM1OPRK1OPRL1 | |
| SCHEMBL30717828 | 0.96 | OPRD1 (0.51) | OPRD1OPRM1OPRK1IL23ROPRL1 | |
| SCHEMBL30717908 | 0.96 | IL23R (0.48) | OPRD1OPRM1OPRK1IL23R | |
| SCHEMBL30717861 | 0.95 | OPRD1 (0.51) | OPRD1OPRM1OPRK1IL23R | |
| SCHEMBL30717880 | 0.94 | OPRD1 (0.52) | OPRD1OPRM1OPRK1IL23R | |
| SCHEMBL30717877 | 0.94 | F2 (0.45) | OPRD1OPRM1IL23R | |
| SCHEMBL30717879 | 0.94 | F2 (0.45) | OPRD1OPRM1IL23R | |
| SCHEMBL30717885 | 0.94 | F2 (0.45) | OPRD1OPRM1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4590664-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025055943-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025055942-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| EP-4511367-A1 | FAP INHIBITORS | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024022332-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023202655-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | OPRD1 4807/4885OPRM1 4813/4885OPRK1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.